OBJECTIVES: False-negative results of endobronchial ultrasound-guided transbronchial needle aspiration in non-small-cell lung cancer staging have shown significant variability in previous studies. The aim of this study was to identify procedure-and tumour-related determinants of endobronchial ultrasound-guided transbronchial needle aspiration false-negative results.
INTRODUCTION
Accurate staging of the mediastinum is crucial for the prognosis and treatment of patients with non-small-cell lung cancer (NSCLC) without evidence of distant metastases. Computer tomography (CT) and positron emission tomography (PET) are current standards for noninvasive mediastinal staging in these patients, but require pathological confirmation by invasive procedures when positive [1] , and may give false-negative results in patients with large and/or central tumours [2] . Minimally invasive methods such as endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) are replacing surgical staging procedures in NSCLC; when these techniques demonstrate mediastinal involvement, no further confirmatory tests are required, because the likelihood of a false-positive result with these procedures is very low [3] . After a negative EBUS-TBNA, however, the use of subsequent staging techniques remains controversial because the negative predictive value of the technique has shown significant variability between studies [4, 5] , and no minimal requirements for a satisfactory EBUS-TBNA procedure have been defined and validated. Accordingly, it has been claimed that EBUS-TBNA is not sufficiently reliable to categorically rule out metastatic involvement of the mediastinum, and secondary confirmative procedures such as oesophageal ultrasonography and/ or cervical mediastinoscopy are recommended when EBUS-TBNA procedures do not show mediastinal malignancy [1, 6] .
The aims of our study were, first, to identify procedure-related, and, second, tumour-related determinants of false-negative results in EBUS-TBNA staging, using nodal dissection as the gold standard for the evaluation of the bronchoscopic procedure. A definition of the minimal requirements to be fulfilled by EBUS-TBNA in order to guarantee a low prevalence of false-negative results will allow a more accurate selection of patients requiring additional staging procedures before the indication of therapeutic surgery.
MATERIALS AND METHODS

Patients
A prospective, multicentre study including patients diagnosed with NSCLC considered operable after EBUS-TBNA was conducted in six university hospitals between 2010 and 2012. Patients with a suspicion of NSCLC were referred by their general practitioner to one of the participating hospitals for diagnosis and/or staging. Staging was performed by EBUS-TBNA in all NSCLC patients who did not show distant metastasis at the first examination. Patients with haemorrhagic diseases or coagulation disorders were excluded from staging by EBUS-TBNA. Noninvasive examinations previous to mediastinal sampling included CT scan of the lung, mediastinum and upper abdomen using multidetector-row spiral CT scanner and PET or PET/ CT scan. Nodes in the mediastinum were considered abnormal when their short-axis diameter was >10 mm, and when they had an absolute maximum standardized uptake value (SUVmax) of ≥4.5, and/or a ≥0.5 ratio of the SUVmax of the mediastinal lymph node to the SUVmax of the primary tumour [1] . Operability was assessed by physical examination, blood tests and pulmonary function tests, and patients considered physically unfit for surgery were excluded from the study. Patients with an EBUS-TBNA procedure negative for malignancy in the mediastinum were staged by cervical mediastinoscopy when their PET scan showed the mediastinum to be hypermetabolic. Therapeutic surgery with nodal dissection was performed after these staging techniques and was considered the gold standard for the present study [7] . The research protocol was approved by the reference regional ethics committee for the project (Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, reference: FIS PS09/ 01612) and by the local ethics committees of all participating centres. Written informed consent was obtained from all participating patients.
Endobronchial ultrasound-guided needle aspiration EBUS was performed in an outpatient setting using a flexible bronchoscope (BFUC180F, Olympus Optical Co., Ltd, Tokyo, Japan) with a distal probe capable of producing linear parallel scans of the mediastinal and peribronchial tissues and a working channel suited for the performance of TBNA under direct ultrasound guidance. Local anaesthesia and sedation were achieved using topical lidocaine spray and intravenous midazolam, propofol and/or fentanyl in accordance with standard recommendations [8] . Mediastinal and lobar nodes with a short-axis diameter of 5 mm or more identified during the procedure were targeted under direct ultrasound visualization with a 22-gauge cytology needle specially designed for EBUS-TBNA (NA-201SX-4022, Olympus Optical Co., Ltd). The needle was guided beyond the bronchoscope channel and then pushed forwards from the sheath and inserted into the tracheal or bronchial wall under ultrasound guidance. Once the needle tip was inside the target, negative pressure was maintained with a syringe at the proximal end of the catheter while the needle was pushed forth and back, releasing the suction when removed from the target structure. Samples were labelled according to whether they had been extracted from a normal node, showing lymphocytic cells and no neoplastic cells, or from a metastatic node, with groups of neoplastic cells. Aspirates containing only bronchial or blood cells, non-diagnostic atypical cells or insufficient material were considered inadequate. Every identified node was sampled three times, unless rapid on-site evaluation performed by a pathologist during the procedure confirmed the adequacy of the sample after the first or the second aspiration [9, 10] .
Pathology
The aspirated material in the needle was recovered and the specimens were placed on slides and fixed with 95% ethanol. The slides were stained for 1 min with haematoxylin when rapid on-site evaluation was performed during the procedure. Papanicolau staining with orange A and eosin was done later in the pathology laboratory. The cytologist classified satisfactory nodal samples as 'normal tissue negative for malignancy' when the sample contained 40 lymphocytes per high-power field in cellular areas of the smear and/or clusters of pigmented macrophages and no neoplastic cells, or as 'metastatic' when recognizable groups of malignant cells were present [11] . Nodes containing only isolated dysplastic, bronchial or blood cells were considered as nonrepresentative of the targeted structure, and were classified as inadequate. Cell blocks were obtained and processed from the specimens recovered whenever extra material was available after the preparation of a minimum of four slides.
Surgical staging
Patients with negative EBUS-TBNA underwent cervical mediastinoscopy when their PET scan showed the mediastinum to be THORACIC abnormal. Cervical mediastinoscopy was performed based on the recommendations of the European Society of Thoracic Surgeons and included station 4R, 4L and 7 samplings regardless of nodal size [1] . Nodal dissection was performed in patients undergoing therapeutic thoracotomy following the recommendations of the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery [12] .
Statistical analysis
Data were entered into a database and analysed using SPSS software, version 18.0 [Chicago, IL, USA]. Categorical variables were expressed as absolute and relative frequencies, continuous variables as means and standard deviations (SDs), and non-normally distributed data as medians and interquartile ranges (IQR). Patients with an EBUS-TBNA procedure attaining satisfactory sampling of at least one mediastinal station were included in the analysis, and false-negative EBUS-TBNA results were calculated using nodal dissection as the gold standard, except in patients with cervical mediastinoscopy showing mediastinal malignancy. The number of mediastinal stations satisfactorily sampled by EBUS-TBNA was calculated, and related to false-negative figures, repeating this analysis for false-negative results in mediastinal stations reachable by EBUS-TBNA, after the exclusion of false-negative results found in non-reachable stations (two-sided χ 2 test). The frequency of false-negative results in the mediastinum was similarly calculated for the non-reachable stations, and related to the number of mediastinal stations satisfactorily sampled (two-sided χ 2 ), assessing also the relationship between the appearance of false-negative results in these out-of-reach stations and the localization of the tumour in the lung (Fisher's exact test).
Firstly, as the main objective, the extensiveness of EBUS-TBNA sampling of mediastinal stations (2R, 2L, 4R, 4L and 7), measured as the number of stations with a minimum of one satisfactorily sampled node (sample containing adequate cytological material) was calculated by bivariate logistic regression as a procedurerelated determinant of false-negative results. Secondly, tumour determinants of false-negative results (size, tumour location, histology and mediastinal extension according to CT and/or PET) were similarly calculated. All procedure-and tumour-related determinants of false-negative results with a bivariate association (P < 0.10) were included in a multivariate logistic model, including the centre as a covariate, to identify factors significantly associated with falsenegative results in stations reachable and non-reachable by EBUS-TBNA. Results were expressed as crude and adjusted odds ratios (ORs) with 95% confidence intervals (95% CI). A P value of ≤0.05 was reported as statistically significant for all statistical tests.
RESULTS
Participating hospitals identified 181 patients with operable NSCLC. Sixteen of them were excluded for further analysis due to inadequate sampling of all EBUS-TBNA targeted nodes. One hundred and sixty-five patients with an EBUS-TBNA procedure showing normal nodes negative for malignancy in at least one mediastinal station were included in the study, 69 of them (41.8%) with enlarged nodes on CT and/or high uptake of fluorodeoxyglucose in the mediastinum on CT/PET (Table 1) .
EBUS-TBNA obtained adequate samples from a median of 2 (IQR 1-2) targeted mediastinal stations, and achieved adequate sampling of three mediastinal stations in 41 patients (24.8%) ( Table 2 ). Pathological staging after surgery identified mediastinal malignancy in 23 of the participants, which were accordingly considered as false-negative EBUS-TBNA procedures (13.9%). Two patients presented with metastasis in more than one mediastinal station (one patient in Stations 4R and 2R and the other patient in Stations 5, 7 and 9). False-negative results were observed mainly in stations reachable by EBUS-TBNA (17 cases, 10.3%), and less often in stations beyond the reach of EBUS-TBNA (7 cases, 4.2%). False-negative results were identified by cervical mediastinoscopy and by nodal dissection in 6 and 17 patients, respectively, nearly half of them in stations beyond the reach of EBUS-TBNA and cervical mediastinoscopy (Table 2) .
False-negative results were clearly related to the extensiveness of EBUS-TBNA sampling. Their prevalence was low (2.4%) when EBUS-TBNA attained a satisfactory sampling of three mediastinal stations, but rose above 10% when satisfactory sampling was attained in only one or two stations (P = 0.043, χ 2 test) ( Table 3) . Considering false-negative results in stations reachable and nonreachable by EBUS-TBNA independently, this inverse relationship between the extensiveness of EBUS-TBNA sampling and falsenegative results was only found for results obtained in reachable stations (P = 0.038, χ 2 test). False-negative results in non-reachable stations were independent of the extensiveness of EBUS-TBNA sampling and were related to tumour location. Six of 7 cases (85.7%) with false-negative results in stations non-reachable by EBUS-TBNA were observed in tumours in the left lung, both in the upper (n = 2) and the lower lobe (n = 4) (Fig. 1) . The difference ≥3 mediastinal stations including a subcarinal station [9] .
with respect to right-sided tumours was statistically significant (P = 0.012, Fisher's exact test). The assessment of determinants of false-negative results in NSCLC staging by EBUS-TBNA in a multivariate model adjusted for centre confirmed the presence of different patterns for stations reachable and unreachable by EBUS-TBNA. Statistically significant risk factors for false-negative results in stations reachable by EBUS-TBNA were an abnormal mediastinum on CT/PET (OR 7.77; 95% CI 2.19-27.51, P = 0.001) and the extensiveness of satisfactory sampling of mediastinal stations (OR 0.37, 95% CI 0.16-0.89, P = 0.026). However, in non-reachable nodes, these determinants were not associated with false-negative results; in this case, the location of the tumour was the only criterion, with a higher risk in left-sided tumours (OR 10.11, 95% CI 1.17-87.52, P = 0.036) ( Table 4) .
DISCUSSION
In our study, false-negative EBUS-TBNA results for mediastinal staging were observed in nearly 15% of patients. Most false negatives were obtained in stations reachable by the technique. EBUS-TBNA obtained satisfactory samples from three mediastinal stations in a quarter of the patients, who showed a prevalence of false-negative results below 3%. False negatives in stations reachable by EBUS-TBNA were clearly related to the extensiveness of sampling, and rose above 10% when nodal sampling obtained satisfactory samples from fewer than three mediastinal stations. This relationship between the extensiveness of EBUS-TBNA sampling and false-negative results was not found in stations beyond the reach of EBUS-TBNA, where the only factor influencing the frequency of false-negative results was the location of the tumour in the left lung. These determinants of false-negative results in stations reachable and unreachable by EBUS-TBNA were confirmed in the multivariate analysis.
We found that EBUS-TBNA achieves satisfactory sampling of three mediastinal stations in one-quarter of patients, and that when this extensiveness is attained; the prevalence of falsenegative results is below 5%. Minimally invasive staging by EBUS-TBNA is now a standard approach for NSCLC; however, no requirements for guaranteeing a low frequency of false-negative results have been defined, and the regular use of additional staging procedures before therapeutic surgery after a negative EBUS-TBNA is recommended in current guidelines [6] . Quality standards for cervical mediastinoscopy require that the procedure should achieve sampling of, at least, both lower paratracheal and subcarinal stations (4R, 4L and 7) in order to be considered representative [1] , and a similar approach has been proposed for EBUS-TBNA [13, 14] . Our results support the use of this quality criterion in EBUS-TBNA sampling. We found that the prevalence of false negatives surpasses 10% when sampling is satisfactory in only one or two mediastinal stations, thus confirming the need for additional staging procedures in this situation. A number of studies have assessed the potential benefit of adding a mediastinoscopy after a negative EBUS-TBNA, most of them retrospective [15] [16] [17] . 
THORACIC
Clinical trials focusing on this issue have concluded that combining EBUS-TBNA and mediastinoscopy resulted in an improvement of the diagnostic yield that is cost-effective [18] [19] [20] [21] . Our results support this approach, since the addition of cervical mediastinoscopy after an unsatisfactory EBUS-TBNA in patients with an abnormal mediastinum on the PET scan significantly reduced false-negative results in reachable nodes in our study to nearly 5%. False-negative results in stations out of reach of EBUS-TBNA had prevalence rates below 5% in our study and, as expected, did not depend on the extensiveness of EBUS-TBNA sampling. In contrast, the false-negative results in these stations were clearly associated with location of the tumour in the left lung. Most of our false-negative results in EBUS-TBNA non-reachable stations 3, 5, 6, 8 and 9 appeared in patients with upper and lower left tumours, suggesting that additional staging procedures are needed in these patients regardless of tumour size and type. Our results are in agreement with several studies that have demonstrated an increase in the diagnostic yield of EBUS-TBNA when used in combination with endoscopic ultrasound-guided needle aspiration, which is able to target malignant nodes in Stations 5, 8 and 9 [19, 20, 22, 23] . Similar results have been reported with the sampling of paraoesophageal stations by means of EBUS-TBNA, locating the device in the oesophagus [24, 25] . Our results suggest that this approach may be especially important in left-sided tumours.
Apart from variables related to the procedure and the tumour, certain other factors can increase the risk of nodal metastases in the mediastinum after a negative EBUS-TBNA. In our study, patients with abnormal mediastinum on either CT or PET scan were more likely to present false-negative results and, in this situation, complementary staging techniques will be needed after a negative EBUS-TBNA procedure before surgery.
All studies including a combination of staging methods have shown better results with a combined approach compared to each single method [19, 20] but a rationale for NSCLC staging needs to be established in order to avoid unnecessary explorations. In this setting, it is essential to identify which subgroups of patients would benefit from additional staging procedures before surgery, and which techniques will be most useful for each patient. Our results support the use of additional procedures like cervical mediastinoscopy in patients with a negative EBUS-TBNA procedure that has not attained a satisfactory sampling of three mediastinal stations, and favour the use of complementary staging techniques as endoscopic ultrasound to reach paraoesophageal and perivascular stations in left-sided tumours. This approach, if confirmed in additional studies, may simplify the staging procedure in lung cancer patients. 
